TFA Therapeutics annual free cash flow
2021
2022
2023
2024
TFA Therapeutics Free Cash Flow (FCF) History (RAJAF)
TFA Therapeutics reported −$37,231 in free cash flow for fiscal 2024, a decrease of $77,468 from the previous fiscal year, with a free cash flow margin of −2.97%.
View full TFA Therapeutics company overviewTFA Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2024 | 2024-12-31 | −$37,231 | −$77,468 | — | −2.97% |
| 2023 | 2023-12-31 | $40,237 | $362,090 | — | +4.56% |
| 2022 | 2022-12-31 | −$321,853 | $143,510 | — | −603.81% |
| 2021 | 2021-12-31 | −$465,363 | — | — | −52.92% |
TFA Therapeutics quarterly free cash flow
No reported data
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|
TFA Therapeutics free cash flow growth trends
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review TFA Therapeutics filings at SEC.gov ↗